<DOC>
	<DOCNO>NCT00604565</DOCNO>
	<brief_summary>In maintenance hemodialysis patient , regular administration parenteral iron addition soluble ferric pyrophosphate ( SFP ) dialysate , compare conventional dialysate , effective preventing development iron deficiency , thereby maintain hemoglobin level ; clinically safe lead oxidative stress inflammation .</brief_summary>
	<brief_title>Delivery Soluble Ferric Pyrophosphate ( SFP ) Via Dialysate Maintain Iron Balance Hemodialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Dialysis Solutions</mesh_term>
	<mesh_term>Iron</mesh_term>
	<criteria>Subjects end stage renal disease undergoing maintenance hemodialysis three time week . Subjects require IV iron time 2 month precede enrollment . Subjects absolute iron deficiency time enrollment In hemodialysis subject `` absolute iron deficiency '' Subjects current malignancy involve site skin . Subjects history drug alcohol abuse within last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Hemodialysis</keyword>
</DOC>